Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis - Related Studies

Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis

This study is not yet open for participant recruitment.

Study NCT00646399. Last updated on October 9, 2008. Information provided by Biosynexus Incorporated

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Staphylococcal Sepsis

2	Additional conditions recognized in this trial
		Bacteremia
		Birth Weight
		Sepsis
		Staphylococcal Infections

3	More general conditions related to this trial
		Bacterial Infections
		Body Weight
		Gram-Positive Bacterial Infections
		Infection
		Inflammation
		Pathologic Processes
		Signs and Symptoms
		Systemic Inflammatory Response Syndrome

4	Interventions listed in this trial
		Pagibaximab (formerly BSYX-A110)

5	Sponsors listed in this trial
		Biosynexus Incorporated